Advanced cardiovascular life support Guidelines 2000: pharmacological changes to the treatment of ventricular fibrillation/pulseless ventricular tachycardia.
Shuster
M
M
Heart and Stroke Foundation of Canada, Ottawa, Canada.
Tang
A
A
D022561:Advanced Cardiac Life Support / Q000379:methods* / Q000592:standards*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D006801:Humans; D017410:Practice Guidelines as Topic / Q000592:standards*; D017180:Tachycardia, Ventricular / Q000188:drug therapy*; D013625:Takayasu Arteritis / Q000188:drug therapy*; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*; D014667:Vasopressins / Q000627:therapeutic use*; D014693:Ventricular Fibrillation / Q000188:drug therapy*
D000889:Anti-Arrhythmia Agents; D014662:Vasoconstrictor Agents; D014667:Vasopressins